4
4
2
2
2
2
1
1
2
2
6
6
3
3
6
6
5
5
4
4
2019
2010
Company (43)University (3)
1 - 10 of 43
Sort by
Patent
Publication NumberCN 109862907 AFiling StatusPatent ApplicationAvailabilityUnknownFiling Date2017-05-02Publication Date2019-06-07
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAb…
Patent
Publication NumberUS 20190144538Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-05-02Publication Date2019-05-16
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAb…
Patent
Publication NumberCA 2755973 CFiling StatusIssued PatentAvailabilityUnknownFiling Date2010-03-22Publication Date2019-04-16
This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production and purification of recombinant proteins in ciliates.
Patent
Publication NumberEP 3452084 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-05-02Publication Date2019-03-13
Patent
Publication NumberIL 262747 D0Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2018-11-04Publication Date2018-12-31
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAb…
Patent
Publication NumberAU 2017260232 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-05-02Publication Date2018-11-29
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAb…
SEC Filing
Accession Number0001409403-18-000002Form TypeDAcceptance Date2018-07-19
Sold $809,770 of $2,000,000 of Equity
Patent
Publication NumberEP 2408926 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2010-03-22Publication Date2018-07-04
Research Grant
IDW81XWH1810030Funding AgencyDepartment of DefenseEffective Date2018-06-01Expiration Date2019-05-31Funding Amount$199,962
Topic Areas: (1) Asthma and (2) Pulmonary Fibrosis Asthma is a chronic disease associated with inflammation and spasms of the airways in the lungs. It is estimated that 26 million people suffer from asthma in the United States, and recent decades have shown a concerning increase in the prevalence of asthma in both children and adults. The costs related to asthma have also been steeply increasing, from ~$12 billion in 1994 to ~$56 billion in 2011. It has also been shown that the frequency…
Patent
Publication NumberWO 2017192567 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-05-02Publication Date2017-11-09
Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAb…
We found 43 documents that match your Search
Research Grants: 11
Patents: 24
SEC Filings: 8

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in